RxDoctor Payments Data

Fakhre Alam, MD

Neurology · Carbondale, ILNPI 1427033828

Payments from drug & device makers

$7,008in general payments, 2019–2025

Across 430 payments — averaging $16.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Teva Pharmaceuticals USA, Inc.$577
  • Novartis$553
  • Pfizer$491
  • UCB, Inc.$453
  • Acadia Pharmaceuticals Inc$413
  • plus $3K from 50 others

What the payments were for

  • Speaking & faculty fees$340%
  • Food & beverage$6,69696%
  • Education$2784%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$7,008 in reported general payments places this provider in the 70th percentile of 790 neurology providers in Illinois.

See all neurology providers in Illinois

Medicare billing

Part B allowed, 2024
$365,830
Medicare patients
953
Services billed
2,619

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate18$105,357
CopaxoneGlatiramer Acetate16$96,855
Nurtec OdtRimegepant Sulfate62$89,510
BriviactBrivaracetam54$83,511
Emgality PenGalcanezumab-Gnlm72$57,697
AmpyraDalfampridine11$43,722
UbrelvyUbrogepant33$39,083
AptiomEslicarbazepine Acetate18$38,388
XcopriCenobamate13$25,218
Aimovig AutoinjectorErenumab-Aooe24$23,768
QuliptaAtogepant20$21,589
Lacosamide225$21,201
BotoxOnabotulinumtoxina14$17,760
BelsomraSuvorexant24$13,665
Pregabalin116$10,071

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$413$105,35718 claims
PfizerNurtec Odt, Dilantin$491$97,99391 claims
Teva Pharmaceuticals USA, Inc.Copaxone$577$96,85516 claims
AbbVieUbrelvy, Qulipta, Botox, Namzaric$1,169$85,98480 claims
UCB, Inc.Briviact$453$83,51154 claims
Acorda Therapeutics, IncAmpyra$68$43,72211 claims
Sunovion Pharmaceuticals Inc.Aptiom$184$38,38818 claims
SK Life Science, Inc.Xcopri$106$25,21813 claims
MerckBelsomra$19$13,66524 claims
Upsher-smith Laboratories LLCTopiramate$16$1,886179 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 790 neurology providers in Illinois.

Other neurology in Carbondale

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →